1. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
- Author
-
Kreye J, Reincke SM, Kornau HC, Sánchez-Sendin E, Corman VM, Liu H, Yuan M, Wu NC, Zhu X, Lee CD, Trimpert J, Höltje M, Dietert K, Stöffler L, von Wardenburg N, van Hoof S, Homeyer MA, Hoffmann J, Abdelgawad A, Gruber AD, Bertzbach LD, Vladimirova D, Li LY, Barthel PC, Skriner K, Hocke AC, Hippenstiel S, Witzenrath M, Suttorp N, Kurth F, Franke C, Endres M, Schmitz D, Jeworowski LM, Richter A, Schmidt ML, Schwarz T, Müller MA, Drosten C, Wendisch D, Sander LE, Osterrieder N, Wilson IA, and Prüss H
- Subjects
- Angiotensin-Converting Enzyme 2, Animals, Antibodies, Monoclonal therapeutic use, Antibodies, Neutralizing immunology, Antibodies, Viral therapeutic use, Antigen-Antibody Reactions, Betacoronavirus immunology, Betacoronavirus pathogenicity, Binding Sites, COVID-19, Coronavirus Infections drug therapy, Coronavirus Infections virology, Cricetinae, Crystallography, X-Ray, Disease Models, Animal, Humans, Kinetics, Lung immunology, Lung metabolism, Lung pathology, Mice, Mice, Inbred C57BL, Molecular Dynamics Simulation, Pandemics, Peptidyl-Dipeptidase A chemistry, Peptidyl-Dipeptidase A metabolism, Pneumonia, Viral drug therapy, Pneumonia, Viral virology, Protein Binding, SARS-CoV-2, Spike Glycoprotein, Coronavirus chemistry, Spike Glycoprotein, Coronavirus immunology, Spike Glycoprotein, Coronavirus metabolism, Antibodies, Monoclonal immunology, Antibodies, Viral immunology, Betacoronavirus metabolism, Coronavirus Infections pathology, Pneumonia, Viral pathology
- Abstract
The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb, CV07-209, neutralized authentic SARS-CoV-2 with an IC
50 value of 3.1 ng/mL. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2-neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss, and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy., Competing Interests: Declaration of Interests Related to this work, the German Center for Neurodegenerative Diseases (DZNE) and Charité-Universitätsmedizin Berlin have filed a patent application on which J.K., S.M.R., H.-C.K., E.S.-S., V.M.C., M.A.M., D.W., L.E.S., and H.P. are named as inventors., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF